

JFW

PATENT  
Attorney Docket No.: CNL-700.01

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the application of: Bai et al.

Serial No.: 10/549,252

Filed: March 13, 2003

Entitled: *A Method for In Vitro Detection of  
Malignant Potential of Dysplasia and Artificial  
Nucleotide Sequences Used Therein*

Examiner: Not yet assigned

Confirmation No.: 2467

Atty. Docket No.: CNL-700.01

Art Unit: 1643

**Certificate of First Class Mailing**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on the date indicated below:

July 10, 2006

Date of Signature and Mail Deposit

By: 

John Barretto

Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Sir/Madam,

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures mailed on May 9, 2006, Applicants submit a paper copy of a Sequence Listing; a computer readable form of the Sequence listing; a Statement to Support Sequence Listing Submission, a copy of the Notice to Comply, a Preliminary Amendment, and a return postcard.

Although it is believed that no fees are due in connection with this submission, the Commissioner is hereby authorized to charge any underpayments, or credit any overpayments, to our Deposit Account No. 06-1448, Ref. CNL-700.01.


Respectfully submitted,

**Customer Number 25181**

Patent Group  
FOLEY HOAG LLP  
155 Seaport Boulevard  
Boston, MA 02210

Telephone: (617) 832-1000  
Facsimile: (617) 832-7000

Dated: July 10, 2006

By:   
Janann Y. Ali, Ph.D.  
Reg. No. 54,958  
Agent for Applicants

mfr e



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/549,252	Hua Bai	CNL-700.01

INTERNATIONAL APPLICATION NO.
-------------------------------

PCT/CN03/00180

I.A. FILING DATE	PRIORITY DATE
------------------	---------------

03/13/2003

25181

FOLEY HOAG, LLP  
 PATENT GROUP, WORLD TRADE CENTER WEST  
 155 SEAPORT BLVD  
 BOSTON, MA 02110

*Sequence Listing*  
**DUE:** 7/9/06  
**FINAL:** 12/9/06

CONFIRMATION NO. 2467

371 FORMALITIES LETTER



\*OC000000018716188\*

Date Mailed: 05/09/2006

## NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

RECEIVED

MAY 16 2006

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

PATENT DEPT.  
 DOCKETING

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed

to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

FREDERICK SMITH

Telephone: (703) 308-9140 EXT 210

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/549,252	PCT/CN03/00180	CNL-700.01

FORM PCT/DO/EO/922 (371 Formalities Notice)